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ABSTRACT 
Type 2 diabetes mellitus (T2DM) has taken the form of a pandemic disease globally as 
people adopt a more western lifestyle. High circulating glucose levels indicates that an 
individual is in the risk zone for developing T2DM. One of the hallmarks for T2DM is 
insulin resistance in skeletal muscle. Skeletal muscle is the primary target for insulin-
stimulated glucose uptake. Thus, it is of clinical importance to understand of how the 
key hormone, insulin, affects the sensitivity of the tissues to maintain the rate of 
glucose uptake, and also how glucose uptake could be altered on a cellular level 
through metabolic switches. The aim for thesis is to investigate whether functional 
insulin signalling, and hence glucose uptake, occurs in incubated skeletal muscle 
specimens. Another aim of this thesis is to understand how the molecular switches 
TBC1D1 and NT5C1A are involved in the regulation of glucose uptake in skeletal 
muscle. 
In paper I, the canonical insulin signalling cascade is investigated in 
homogenates and cross-sections of skeletal muscle. Muscle specimens were incubated 
in vitro, which is a commonly used experimental technique, to measure glucose uptake 
and utilisation in skeletal muscle. We show that the canonical pathway of insulin 
signalling is activated throughout the muscle specimen due to insulin diffusion. We 
also validate the preparation for the study of insulin signalling. We provide evidence 
that the experimental approach is valid to assess insulin signalling. 
In paper II the effect of silencing the NT5C1A enzyme in skeletal muscle and 
NT5C2 in cultured myotubes and intact muscle was investigated. We hypothesised that 
AMPK could be increased if less AMP was hydrolysed as a result of a reduction in the 
expression of the NT5-enzyme. We demonstrate that in myotubes grown from human 
biopsies, as well as in mouse tibialis anterior muscle, NT5C silencing increases 
phosphorylation of AMPK and ACC through changes in the AMP:ATP ratio to thereby 
increase glucose uptake and lipid oxidation. This means that there is alternative 
approach to activate AMPK and increase glucose uptake, rather than exercise or 
chemical stimulation, which is a common way to activate metabolism.  
In paper III we investigate the role of TBC1D1 in insulin signalling and 
metabolism. We provide evidence that the TBC1D1-deficient congenic B6.SJL-
Nob1.10 (SJL/SJL) mice have enhanced suppression of hepatic glucose production 
during the euglycemic-hyperinsulinemic clamp. Moreover, glucose uptake in extensor 
digitorum longus (EDL) and tibialis anterior muscle was increased during an insulin-
stimulated 2-deoxyglucose clamp. Conversely, in vitro glucose uptake in response to 
insulin, contraction or AICAR was impaired in EDL muscle, but not in soleus muscle 
from the SJL/SJL mouse. These data provide evidence that TBC1D1 is a regulator of 
glucose transport and metabolism in skeletal muscle. 
In conclusion, insulin signalling is functional in incubated skeletal muscle 
specimens. Moreover, the molecular switches TBC1D1 and NT5C1A have high impact 
on glucose uptake in skeletal muscle, which is of great importance for the investigation 
and understanding of T2DM. 
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1 INTRODUCTION 
The nutrients for most living organisms can be divided into three major groups, fat, 
carbohydrates and proteins. Humans tend to eat various sources of nutrients and have 
done so in a historical perspective, with some nutrition sources being rare and some 
abundant. What is rare and what is abundant has changed over the last few centuries, 
and in the western world in particular, now all nutrients are abundant. In an 
evolutionary perspective, humans have tended to prefer rare nutrients, i.e. 
carbohydrates, if they had the opportunity. Humans still display this same behaviour, 
with the difference that there is an oversupply of the historically rare carbohydrates 
(Cordain et al., 2000). After a carbohydrate rich meal, blood glucose levels rise quickly 
and there is a need for levels to be normalized. This normalisation is mediated by the 
hormone insulin (Banting et al., 1922). Skeletal muscle is the major site for clearing 
blood glucose in response to insulin, and accounts for 75% of the glucose disposal 
(Baron et al., 1988; Cline et al., 1999). The main glucose transporter in skeletal muscle 
is the glucose transporter 4 (GLUT4) (Cushman & Wardzala, 1980; Fukumoto et al., 
1989), which under basal conditions is located in the cytoplasm. GLUT4 translocates to 
the plasma membrane to facilitate glucose transport in response to insulin or 
contraction (Birnbaum, 1989). Type 2 diabetes mellitus (T2DM) is characterized by 
defects in skeletal muscle glucose uptake (Alberti & Zimmet, 1998). The underlying 
fault can be regulatory, like a defective signalling pathway, or it can be a genetic defect 
with one or several genes that are inactive or over-active, or both. A major contributing 
factor to the development of insulin resistance in T2DM is lifestyle and food habits, 
with the simple equation: that what we eat, the body must dispose, either store or use as 
fuel/energy source (Bjorntorp & Sjostrom, 1978). 
 
 
1.1 TYPE 2 DIABETES MELLITUS 
There is also another form of diabetes called type 1 diabetes mellitus, which is the 
result of an autoimmune destruction of the pancreatic beta cells, which produce insulin. 
However, the work in this thesis is focused on T2DM. The criterion for getting the 
diagnosis of T2DM is a blood glucose value above a specific value. The blood glucose 
value is usually measured as fasting plasma glucose level in millimol per litre (mmol/l), 
and a fasting concentration of 6.1 mmol/l glucose or above is considered as pathologic 
and indicative of T2DM (Alberti & Zimmet, 1998). A two hour blood glucose value 
after an oral glucose tolerance test (OGTT) that is above 11.1 mmol/l is also a criterion 
for T2DM according to the International Diabetes Federation (www.idf.org). 
Individuals with T2DM show a lower whole body glucose utilisation, which is mainly 
the result of reduced insulin-mediated glucose uptake in skeletal muscle (DeFronzo et 
al., 1985; DeFronzo, 1988). The golden standard to investigate insulin sensitivity in 
medical research is the hyperinsulinemic euglycemic clamp, during which skeletal 
muscles account for 80-90% of glucose disposal under insulin-stimulated conditions 
(DeFronzo, 1988). Insulin signalling has also been shown to be impaired in T2DM 
patients at the level of insulin binding to the insulin binding to the insulin receptor (IR) 
(Caro et al., 1987), but also in the phosphorylation of the IR, which is the consecutive 
step after insulin had bound (Arner et al., 1987; Krook et al., 2000).  
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1.2 OBESITY 
High levels of circulating free fatty acids and large fat depots seem to contribute to 
skeletal muscle insulin resistance (Boden & Chen, 1995; Roden et al., 1996; Brechtel et 
al., 2001). Insulin resistance is one factor that connects obesity to the world-wide 
increase of T2DM. T2DM is considered as a metabolic disorder, which is primarily 
characterised by insulin resistance, hyperglycemia and impaired insulin secretion 
(DeFronzo et al., 1985). A person is considered obese if the body mass index (BMI) is 
above 30 kg/m2, and overweight if the BMI is equal to or over 25 kg/m2. The number 
of obese people is growing dramatically worldwide and since 1980, the number of 
obese people has doubled (WHO, 2011). In 2008, 200 million men and 300 million 
women 20 years or older were obese, and in 2010, almost 43 million children younger 
than five years of age were overweight (WHO, 2011). The stated main reason for this 
trend for increased obesity according to the WHO is increased food intake and 
decreased physical activity. 
 
 
1.3 HYPERINSULINEMIC EUGLYCEMIC CLAMP 
The hyperinsulinemic euglycemic clamp measures the amount of glucose necessary to 
compensate for the particular amount of intravenously infused insulin, without causing 
hypoglycemia (Shen et al., 1970; DeFronzo et al., 1979b). In humans, after an 
overnight fast, insulin is infused through a vein at a constant rate of 5-120 mU m-2 min-
1 and 20% glucose solution is infused (GIR) to “clamp” blood glucose at normal levels, 
around 5-5.5 mmol/l. Blood glucose levels are checked every 5 minutes. The infused 
insulin sets a new, higher basal insulin level (hyperinsulinemic), which supresses 
hepatic glucose production (HGP) and increases glucose disposal in skeletal muscle 
and adipose tissue. Assuming that HGP is totally supressed by the infused insulin, then 
GIR is equal to the glucose disposal rate, which in turn is equal to the whole body 
glucose disposal rate (M) for that particular level of hyperinsulinemia. The infused 
glucose can be radioactive labelled, [3-3H]glucose, and an infusion of [3-3H]glucose 3 
hours before and throughout the clamp makes it possible to measure insulin-stimulated 
whole body glucose turnover rate and also HGP rate. The insulin-stimulated whole 
body glucose turnover rate is determined as the ratio of infused [3-3H]glucose 
(dpm/min) to the specific plasma glucose activity for the last 30 min of the clamp. 
Basal HGP is calculated by the ratio of basal GIR (dpm/min) to the basal plasma 
glucose specific activity (dpm/µmol). To calculate insulin-stimulated HGP, the glucose 
infusion rate is subtracted from the whole body glucose turnover rate. The test takes 
approximately two hours, where a low insulin infusion rate is useful to assess the liver 
response and a high insulin infusion rate is used to assess the peripheral insulin 
response. As mentioned before, this test is mostly used in medical research and not in 
clinical care, where the oral glucose tolerance test (described below) is used instead 
(DeFronzo et al., 1979a; Kim, 2009). 
 
 
1.4 ORAL GLUCOSE TOLERANCE TEST 
Impaired glucose tolerance (IGT) is one of the hallmarks for the diagnosis a person 
with increased risk for developing T2DM. A common test to assess a person’s glucose 
tolerance is called the Oral Glucose Tolerance Test (OGTT). The OGTT measures 
blood glucose two hours after an oral consumption of 75g glucose. Glucose levels 
below 7.8 mmol/l are considered as normal glucose tolerant (NGT), glucose values 
between 7.8 and 11.1 mmol/l are considered as IGT and glucose values above 11.1 
   3 
mmol/l are considered as T2DM (Figure 1). The fasting glucose values for IGT should 
be below 7.0 mmol/l, which means that the glucose value is too high to be normal, but 
too low to be classified as T2DM, according to (www.idf.org). 
 
 
 
Figure 1: Typical blood 
glucose and insulin values 
during OGTT for NGT 
(Dotted line), IGT (Dashed 
line) and T2DM (Solid line) 
patients. Blue lines are 
glucose levels and red lines 
are insulin levels.  
 
 
 
 
 
 
 
 
 
 
 
 
1.5 INSULIN SENSITIVE TISSUES 
Skeletal muscle, adipose tissue and liver are the major organs that respond to insulin. 
Regulatory mechanisms in these tissues interact mainly with insulin and glucagon. 
Insulin production and secretion is performed by the pancreatic β-cells in the 
Langerhans islets in response to high blood glucose (hyperglycaemia), which decreases 
glucose production (gluconeogenesis) in the liver, reviewed in (Zierath & Wallberg-
Henriksson, 1992; Kolaczynski & Caro, 1998; DeFronzo, 2010), and increases glucose 
disposal in adipose and skeletal muscle. Glucagon is secreted from the pancreatic α-
cells in the Langerhans islets in response to low blood glucose levels (hypoglycaemia). 
Glucagon increases gluconeogenesis in the liver, reviewed in (Thorens, 2008; Edgerton 
et al., 2009). During hypoglycemia, glucagon is secreted into the circulation reaching 
the liver, where it increases the gluconeogenesis. Under hyperglycemic conditions, 
insulin is secreted into the circulation, which decreases gluconeogenesis in the liver and 
increases glucose uptake in peripheral tissues. In T2DM, insulin secretion is insufficient 
to lower the blood glucose level. This can be due insufficient amounts of secreted 
insulin or insulin resistance in peripheral tissues. A first indication of the development 
of T2DM is often elevated glucose levels and hyperinsulinemia as a compensation for 
peripheral insulin resistance. However, after a period of time, with increasing blood 
insulin levels, the pancreatic β-cells fails to secrete the required amount of insulin to 
maintain normoglycemia, and the insulin level starts to decrease and insulin therapy is 
required to maintain glucose homeostasis, reviewed in (DeFronzo, 2010). 
 
1.6 SKELETAL MUSCLE 
Skeletal muscle is a primary target for insulin action. Mammalian skeletal muscle 
exhibits a high degree of metabolic flexibility and can shift nutrient source according to 
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various physiological demands. Calorie restriction both in humans and rodents 
increases insulin sensitivity in skeletal muscle (Kelley et al., 1993; Cartee & Dean, 
1994). Overfeeding (in rodents) induces insulin resistance in skeletal muscle (Wang et 
al., 2001). Skeletal muscle is composed of individual fibres, which in turn display 
differences in contractile and metabolic properties. The individual composition of 
fibres constitutes the metabolic and contractile properties of the muscle. A rough 
classification of skeletal muscle fibres, depending on their contractile and metabolic 
properties, is to divide them into: oxidative slow-twitch red fibres (type 1) and 
glycolytic fast-twitch white fibres (type 2). The glycolytic fibres are less sensitive to 
insulin compared to the oxidative fibres. The contractile properties are decided by the 
ratio of myosin heavy chain isoforms (MHC), the most common MHC types are 1, 2A, 
2X and 2B (Schiaffino et al., 1989), where muscles composed of predominantly type 1 
fibres display slow twitch properties and are highly oxidative, whereas muscles 
composed mainly of type 2B fibres display fast twitch properties and are mainly 
composed of glycolytic fibres.  
 
1.6.1 Exercise training 
One well known way to improve insulin sensitivity is to exercise (Mikines et al., 1989). 
Even a single bout of endurance exercise is sufficient to increase insulin sensitivity in 
skeletal muscle (Richter et al., 1982). Exercise training can transform the phenotype of 
type 2 muscle fibres from glycolytic to more oxidative characteristics (Schantz & 
Henriksson, 1983). Exercise training has also proven to have positive impact on T2DM, 
with increased oxidative capacity, such that fatty acids are used as an energy source and 
glycogen stores are increased in muscle due to increased insulin sensitivity. Taken 
together exercise training decreases the risk of T2DM by more than 50% (Rubin et al., 
2002; Ilanne-Parikka et al., 2008). 
 
1.6.2 Insulin signalling in skeletal muscle 
The insulin molecule binds to the IR on the cell membrane. This results in 
autophosphorylation of the IR (Van Obberghen et al., 1983) and initiates a signalling 
cascade downstream of the IR (Kahn et al., 1972; Kahn & White, 1988). The Insulin 
Receptor Substrate (IRS) is first activated in the cascade, and after that 
Phosphatidylinositol-3-kinase (PI3-K), Akt and glycogen synthase kinase 3 (GSK3) 
(Cross et al., 1995; Lee et al., 1995) are activated. The insulin signalling cascade affects 
glycogenesis (Parker et al., 1983; Roach, 2002; Jensen & Lai, 2009) through 
phosphorylation of Akt on serine 473 which in turn phosphorylates GSK3 on serine 21 
and serine 9, the phosphorylation of GSK3 increases glycogen synthesis by raising the 
activity of the enzyme glycogen synthase which facilitates the metabolism of glucose 
into glycogen (Rodriguez & Fliesler, 1988; Pillay & Makgoba, 1991; Smythe & Cohen, 
1991). Glycogenesis is inhibited by high levels of glycogen and accelerated by high 
levels of glucose-6-phosphate (G6P). G6P is the first metabolite during glycolysis. G6P 
is formed when hexokinase phosphorylates glucose (Roach, 2002; Jensen et al., 2006) 
Akt also phosphorylates the TBC1 domain family member 1 (TBC1D1) and TBC1D4 
and these molecules are considered as the closest signalling proteins to GLUT4, but 
also the most distant in the insulin signalling cascade controlling GLUT4 translocation 
(Kane et al., 2002; Roach et al., 2007). Figure 2 shows a schematic overview of insulin 
signalling in skeletal muscle. Insulin signalling has been thoroughly studied in various 
cell systems but not so extensively in whole skeletal muscles specimens. Skeletal 
muscles are multi cellular structures which add an extra dimension in of complexity in 
the form of fibre bundles grouped into a whole skeletal muscle. 
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1.6.3 Glucose transport in skeletal muscle 
As mentioned above, GLUT4 is the main transporter of glucose in skeletal muscle, and 
the two major mechanisms by which glucose is transported into the cell is through 
muscle contraction and/or insulin signalling (Holloszy & Hansen, 1996; Tanti et al., 
1997). Muscle contraction depletes the fibres internal stores of ATP and hence, 
increases the concentration of AMP (Hardie et al., 1999). A low intracellular energy 
state is indicated with high concentrations of AMP. The depletion of ATP increases 
glucose transport by translocating GLUT4 to the plasma membrane and glucose 
diffusion is facilitated. One of the molecular mechanisms involved in this insulin-
independent pathway is via AMP-activated protein kinase (AMPK) (Musi et al., 2001). 
A chemical compound, 5-aminoimidazole-4-carboxamide-1-β-D-ribofluranotide 
(AICAR), mimics the effect of AMP on AMPK (Merrill et al., 1997). AICAR is 
metabolized to a monophosphorylated derivative (ZMP) by adenosine kinase (AK), 
which is an analogue of AMP and activates AMPK by increasing the ZMP/ATP ratio. 
AICAR is used as a biochemical agent to mimic the activation of AMPK by AMP and 
it is used to study the role of AMPK in metabolism (Corton et al., 1995). 
 
1.6.4 Glucose transport and TBC1D1 
In the basal state, GLUT4 can be tethered and prevented from reaching the plasma 
membrane by special Rab GTPase activating proteins namely TBC1D1 and TBC1D4. 
Both TBC1D1 and TBC1D4 contain GAP domains to which specific Rab protein bind. 
When bound, the glutamine residue in the Rab protein gets aligned with arginine in the 
TBC domain and this this accelerates the hydrolysis of GTP by stabilizing the protein 
to protein interaction (Scheffzek et al., 1998; Rak et al., 2000). Rab proteins are small 
G proteins that are required for vesicle trafficking. The function of G proteins is to 
work like a molecular switch; if they have bound GTP they are “on” and if they have 
bound GDP they are “off”. TBC1D1 is active in its unphosphorylated state and thereby 
tethers GLUT4 molecules by hydrolysing GTP to GDP and hence decreasing the rate 
of glucose transport into the cell (Figure 2). Mice lacking TBC1D1 through a natural 
occurring deletion in the gene have reduced GLUT4 protein levels (Chadt et al., 2008). 
Reduced expression of TBC1D1 in skeletal muscle cells increases both the uptake and 
oxidation of fatty acids (Chadt et al., 2008). To make a rough distinction of the tissue 
distribution, one can say that TBC1D1 is the most abundant in type II skeletal muscle 
fibres, whereas TBC1D4 is most abundant in type I skeletal muscle fibres and white 
adipose tissue from mouse. Nevertheless, the precise role of TBC1D1 in the regulation 
of cellular response to insulin or activators of the cellular stress signalling cascade is 
unknown. Furthermore, the role of TBC1D1 in the regulation of whole body glucose 
uptake has not been investigated. 
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Figure 2: Insulin-dependent and -independent glucose uptake. Insulin stimulation leads to the 
phosphorylation of Akt, which then inactivates TBC1D1. TBC1D1 can also be phosphorylated by 
AMPK. When TBC1D1 is phosphorylated, the GAP binding site is unable to bind and hydrolyse GTP to 
GDP, which in turn makes the Rab-protein active. Hence, GLUT4 translocation is promoted and glucose 
uptake increases. 
 
1.6.5 Fatty acid metabolism in skeletal muscle 
Fatty acid oxidation occurs in the mitochondria by β-oxidation, and the availability of 
fatty acids is the regulating step for oxidation, reviewed in (Ruderman et al., 1999). The 
enzyme carnitine palmitoyl transferase 1 determines the rate of fatty acid oxidation by 
controlling the transfer of long chain fatty acids into the mitochondria (McGarry, 
1995). Malonyl-CoA is the substrate, carboxylated from acetyl-CoA, which enters the 
citric acid cycle. Acetyl-CoA is the product from the break-down of fatty acids in the 
form Acyl-CoA in the mitochondria. The formation of malonyl-CoA can be prevented 
by blocking the enzyme acetyl-CoA carboxylase (ACC), which forms malonyl-CoA. 
AMPK is also involved in the formation of malonyl-CoA. When AMPK is activated it 
blocks ACC activity by phosphorylation (Winder & Hardie, 1996). AMPK also 
promotes (Saha et al., 2000) and blocks (Habinowski et al., 2001) decarboxylation of 
malonyl-CoA by acting on the enzyme malonyl-CoA decarboxylase. Exercise increases 
fatty acid oxidation in skeletal muscle. Figure 3 provides a schematic picture of fatty 
acid metabolism in skeletal muscle. 
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Figure 3: Fatty acid oxidation in skeletal muscle. Phosphorylated AMPK inhibits fatty acid oxidation by 
phosphorylation of the enzyme ACC. TBC1D1 has a negative impact on the uptake of fatty acids and 
fatty acid oxidation. AMPK has a dubious role regarding the enzyme MCD, both as activator and 
suppressor; this is reflected by the question mark on the line between AMPK and MCD. 
 
 
1.7 5’-NUCLEOTIDASES 
5’-Nucleotidases (NT5s) are a family of enzymes that catalyse the hydrolysis of non-
cyclic nucleotide monophosphates to nucleosides and inorganic phosphate. The role of 
intracellular NT5s is to maintain a balance in DNA and RNA synthesis by regulating 
the intracellular pool of nucleotides (Figure 4). NT5C1 prefers AMP as a substrate and 
is highly expressed in heart and skeletal muscle (Gibson & Drummond, 1972). NT5C2 
prefers Guanine Monophosphate (GMP) and Inosine Monophosphate (IMP) as 
substrates, but has an overlapping affinity towards AMP (Banditelli et al., 1996). The 
NT5-enzymes play a central role in maintaining the intracellular levels of ADP and 
ATP and can therefore indirectly regulate the AMPK activity. NT5-enzymes may 
regulate the catabolic pathways and production of ATP via AMPK (Spychala et al., 
1988; Hanisch et al., 2006; Careddu et al., 2008). 
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Figure 4: Nucleotidases in skeletal muscle. NT5C1A dephosphorylates AMP to adenosine which then 
can be transported out of cell.  NT5C2 dephosphorylates IMP to Inosine which then can be transported 
out of the cell. This will negatively influence the intracellular available pool of nucleotides (e.g. AMP), 
leading to less ADP and ATP. 
 
Nucleotides do not appear to be transported over the plasma membrane. However, after 
the NT5-enzyme has dephosphorylated the nucleotide to a nucleoside, it can be 
transported out of the cell by facilitated diffusion (Gazziola et al., 2001; Hunsucker et 
al., 2005). 
 
Given the central role of NT5-enzymes in controlling and maintaining the intracellular 
levels of ADP and ATP they may provide an alternative pathway to indirectly regulate 
the AMPK activity and hence control glucose and lipid metabolism. Thus, gene 
silencing of NT5-enzymes to increase the intracellular availability of AMP may 
increase AMPK activity and metabolism. However, this approach has yet to be tested. 
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2 AIM OF THE THESIS 
The hypothesis for this thesis is that insulin signalling is triggered throughout the 
muscle specimen during in vitro incubation. TBC1D1 and NT5C1A are molecular 
switches affecting glucose uptake in skeletal muscle. To this end in vitro and in vivo 
metabolic experiments in mouse skeletal muscle, and cultured human muscle have been 
performed. Specific aims are outlined below. 
 
¾ To determine if the insulin signalling cascade is triggered due to diffused 
insulin in in vitro incubation of muscle specimens. 
¾ Specifically, we determined whether insulin is able to diffuse across the 
entire muscle specimen in sufficient amounts to activate signalling cascades 
to promote glucose uptake and glycogenesis within isolated mouse skeletal 
muscle. 
 
¾ To investigate the role of 5´-nucleotidases in skeletal muscle metabolism. 
¾ We hypothesized that gene silencing of NT5 enzymes to increase the 
intracellular availability of AMP would increase AMPK activity and 
metabolism in order to elucidate the role of cytosolic NT5 in metabolic 
responses linked to the development of insulin resistance in obesity and type 
2 diabetes mellitus. 
 
¾ To validate the role of TBC1D1 in skeletal muscle metabolism. 
¾ We determined whether TBC1D1 is involved in insulin, as well as energy-
sensing signals controlling skeletal muscle and whole body metabolism. 
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3 METHODS 
 
3.1 ANIMALS 
Mice were maintained in light and temperature controlled environment and had free 
access to water and standard rodent chow. Mice used for the in vitro experiments were 
anaesthetized with Avertin (2,2,2)-Tribromo ethanol 99% (0.5 µl per gram of body 
weight, intraperitoneal), and thereafter Soleus and EDL muscles were rapidly dissected 
and kept in a oxygenated (95% O2, 5% CO2) Krebs-Henseleit bicarbonate buffer 
(KHB) at 30°C. Mice studied for the in vivo experiments (clamp surgery and 
electroporation) were anaesthetized with Isoflurane (~2% of breathing air), and a pain 
killer was administered (Rimadyl, subcutaneously, 5 mg/kg bodyweight) directly after 
the surgical procedure and the following day. All experimental procedures were 
approved by the regional Ethical Committee in Stockholm. 
 
3.1.1 Wild type animals 
The C57Bl/6J mouse was used as a wild type (control) animal in the in vitro muscle 
incubations, unless otherwise stated. 
 
3.1.2 TBC1D1 animals 
The TBC1D1 animals have a 7 base pair deletion in the TBC1D1 gene in exon 18. The 
deletion gives a TBC1D1-deficient congenic B6.SJL-Nob1.10 (SJL/SJL) mouse. The 
transgenic TBC1D1 mice and litter mates homozygous for the wild type exon 18 
(B6/B6) were studied (Chadt et al., 2008). 
 
 
3.2 METABOLIC MEASUREMENTS AFTER IN VITRO INCUBATION 
The incubation media used for the in vitro study was composed of a Krebs-Henseleit 
bicarbonate buffer (KHB) supplemented as specified in the Papers for each particular 
experiment. The basal incubation buffer contained 5 mM glucose, 15 mM mannitol, 5 
mM HEPES and 0.1% bovine serum albumin (BSA). Muscles were incubated at 30°C 
oxygenated (95% O2, 5% CO2) in a shaking water bath. The animals were fasted 4 
hours before each experiment. 
 
3.2.1 Insulin and AICAR stimulated glucose transport 
The assessment of glucose transport in in-vitro incubated mouse skeletal muscle 
consists of four incubation steps: 
Recovery Æ Pre-incubation Æ Rinse Æ Hot incubation, below follows a more 
detailed description of each step.  
Recovery continued for 30 min in basal media for the muscles to recover from surgery. 
Pre-incubation was performed in either basal, insulin (120 nM) or AICAR (2 mM) 
complemented KHB.  
Rinse continuous for 10 min in which the muscle was incubated in a glucose-free 
buffer containing 20 mM mannitol.  
Hot incubation was performed with radioactive labelled tracer for 30 min, in the 
presence of either AICAR (2 mM) or insulin (120 nM) with KHB supplemented with 1 
mM 2-deoxy-[1,2,3H]glucose (2.5 µCi/ml) and 19 mM [14C]mannitol. The last step was 
included to wash the muscles in ice-cold KHB. The muscles were then blotted on filter 
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paper, and freeze-clamped with a precooled tong in liquid nitrogen. Thereafter the 
muscles were stored in -80°C until analysis. Glucose transport was measured by 
scintillation counting of the intracellular accumulation of 2-deoxy-[1,2,3H]glucose and 
expressed as nmol glucose per mg of protein per 30 min. 
 
3.2.2 Contraction-stimulated glucose transport 
For the determination of contraction-induced glucose uptake, the same protocol was 
used as described for insulin- and AICAR-stimulated glucose transport, with some 
minor modifications. The pre-incubation step was exchanged for a 10 min contraction 
stimulus. The isolated muscles were placed in an incubation chamber with continuously 
oxygenated basal KHB. The distal tendons were fixed at the bottom of the chamber and 
proximal tendons were connected to a force transducer (Harvard Apparatus) and the 
resting tension was set to 0.5 g. The muscles were stimulated at frequency of 100 Hz, 
0.2 ms pulse length with 20 V, every 2 sec for 10 min. Figure 5 shows the contraction 
apparatus. 
 
 
Figure 5: The contraction 
apparatus, along with the 
Harvard Apparatus force 
transducer, the green 
arrows on the close-up 
shows a muscle specimen 
during the contraction 
procedure placed in a 
chamber filled with KHB. 
 
 
 
 
 
 
3.2.3 Glucose incorporation into glycogen and glucose oxidation 
Glucose incorporation into glycogen and glucose oxidation was assessed in Soleus and 
EDL muscles. Muscles were incubated at 30°C for 60 min in 2 ml of KHB 
supplemented with 5 mM [U-14C]glucose (0.3 µCi/ml), in a flask sealed with a rubber 
stopper. Each flask contained a centre-well which collected the CO2 released into the 
media from the muscle. Immediately after incubation, 200 µl of protosol was injected 
into the centre-well via a syringe through the rubber cap, and the flasks were placed in 
ice-cold water bath for 3 min. Thereafter, the flasks were quickly opened and the 
muscle was removed and placed on ice-cold filter paper and trimmed of tendons, 
weighed and freeze clamped. After the flasks were resealed, 15% PCA was injected via 
a syringe into the media, followed by continuous incubation for 60 min and the released 
[U-14C]CO2 was collected into the centre-well containing protosol. After the incubation, 
150 µl of the protosol in the centre-well was pipetted into 20 ml scintillation vials. This 
step was included to ensure that the same volume was used for scintillation counting of 
all samples, rather than taking the whole centre-well and placing it in the scintillation 
vial. Using the latter approach, it could be possible to get different volumes and also 
contamination from the media on the outside of the centre well. Thereafter, 10 ml of 
scintillation fluid and 200 μl of 5N HCL was added to all vials, after which they were 
mixed and stored at 4°Cfor 60 min before counting in the β-counter. The incubated 
muscles were dissolved with 0.5 ml of 1M NaOH at 70°C for 30 min. Thereafter, 0.5 
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ml of 20% TCA was added for deproteinization, the samples were vortexed and 
subjected to centrifugation at 3,500 g at 10°C for 15 min. The supernatants were 
pipetted into new tubes, to which 200 µl of glycogen solution (100 mg glycogen in 5 
ml of dH2O) and 2 ml of ethanol was added. This glycogen serves as a carrier for the 
radioactive glycogen. The tubes were placed at -20°C overnight, after which the tubes 
were subjected to centrifugation for 15 min at 2,000 g. Thereafter, the supernatant was 
discarded and the pellet was dissolved in 0.7 ml of dH2O. Aliquots of 500 µl were 
measured in scintillation vials with the same procedure as for the released CO2. 
 
 
3.3 METABOLIC MEASUREMENTS IN VIVO 
 
3.3.1  Euglycemic Hyperinsulinemic clamp 
The mice for clamp experiments underwent surgery 7 days before the actual 
experiment. During the surgery, a catheter was placed in the left jugular vein towards 
the heart. The catheter was drawn up on neck of the mouse and then connected to a 
pump, which was used for the insulin and glucose infusion. Animals were fasted 4 
hours before the actual clamp experiment. 
 
3.3.1.1 Euglycemic Hyperinsulinemic clamp 
During the euglycemic hyperinsulinemic clamp, glucose turnover rate (GTR) and 
hepatic glucose production (HGP) were determined, approximately 60 min after tracer 
infusion. GTR was measured in the basal state, with a constant infusion of [3-3H] 
glucose (0.09 µCi/min). The bolus injection was 2.5 µCi. The priming dose of insulin 
(25 mU/kg) was administered before the constant rate of insulin infusion (2.5 
mU/kg/min). Steady state was reached approximately 60 min after administering a 
bolus of insulin. During steady state, blood samples were obtained and used to 
measure HPG (the average glucose infusion rate subtracted from the glucose 
utilisation) and whole body glucose utilisation. Blood samples were taken at the basal 
and insulin-stimulated condition to measure circulating insulin levels. 
 
3.3.1.2 2-Deoxyglucose Euglycemic Hyperinsulinemic clamp 
The 2-deoxyglucose euglycemic hyperinsulinemic (2-DOG) clamp was performed to 
access tissue-specific glucose uptake. A bolus of insulin (40 mU) was administered at 
the start of the clamp and the insulin infusion rate was maintained at 75 mU/min/kg. 
Blood glucose values were monitored at 5 min interval. The glucose infusion was 
increased until the target basal glucose value was reached and remained stable. At this 
stage the tracer was injected (3 µCi) and blood samples were taken at 0, 3, 6, 10, 15, 
20, 30, 40 and 60 min. At this point the animals were euthanized with an overdose of 
sodium pentobarbital and the tissues were collected. The tissues were lysed in 0.5 ml 
NaOH for 60 min at 60°C and neutralized with 0.5 ml of HCL. The homogenates was 
divided and into two samples; 0.2 ml for analysis with Ba(OH)2 and ZnSO4 and 0.2 ml 
taken for analysis with 6% PCA. The samples were mixed with a vortex and 
centrifuged. Thereafter, 0.8 ml of the supernatant was pipetted into a scintillation vial 
containing 10 ml of scintillation fluid. The samples were subjected to scintillation 
counting. The results were calculated as [Ba(OH)2,ZnSO4]-cpm values subtracted from 
the [PCA]-cpm values. 
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3.4 ELECTROPORATION 
With electroporation, a polar molecule like a plasmid or DNA is introduced into the 
cell through the membrane by electrical stimulation. The electrical stimulation creates 
pores in the cell membrane in which foreign DNA can enter, the pores will close by 
themselves and the DNA are trapped inside the cell where it can use the cells 
endogenous machinery to produce mRNA and thereby protein (McMahon & Wells, 
2004). 
 
3.4.1 Knock down of NT5C1A with electroporation 
To reduce expression of NT5C1A, a pool of shRNA plasmids targeted against 
NT5C1A (SABiociences) was used. The tibialis anterior, in 12-14 weeks old C57Bl/6 
mice was targeted. Prior to electroporation, the tibialis anterior muscle was injected 
with hyaluronidase to permeabilize the muscle. After a 2 hour incubation, the 
plasmids were injected and thereafter the leg was electrically stimulated with the 
ECM 830 square wave electroporation system (BTX, Harvard apparatus, Holliston, 
MA), using contact gel to ensure good conductivity with the calliper electrodes. 
 
3.4.1.1 Glucose uptake in tibialis anterior muscle after electroporation 
Mice were fasted for 4 hours, thereafter a bolus of glucose (3 g/kg) was administered 
by gavage. An intraperitoneal injection of [3H]-glucose (4.5 µl 3H-2DG per 100 µl of 
saline per animal, 1 mCi/ml) was administered. 2 hours after injection the tibialis 
anterior was dissected out and frozen in liquid nitrogen. Muscles were homogenised in-
ice cold buffer (10% glycerol, 5 mM sodium pyrosulphate, 13.7 mM NaCl, 2.7 mM 
KCl, 1 mM MgCl2, 20 mM Tris (pH 7.8), 1% Triton X100, 10 mM NaF, 1 mM 
EDTA, 0.2 mM phenylmethylsulfonyl fluoride, 1 μg/ml aprotinin, 1 μg/ml leupeptin, 
0.5 mM sodium vandanate, 1 mM benzamidine, 1 μM microcystin) using a motor 
driven pestle for 20 seconds. Samples were rotated for 1 hour at 4°C, and then 
subjected to centrifugation (12,000 g for 10 min at 4°C) after which, 30 µl of the 
supernatant was subjected to scintillation counting, and the remaining portion of the 
supernatant was stored at -80°C for western blot analysis. 
 
 
3.5 IMMUNOHISTOCHEMISTRY 
 
3.5.1 Cryostat sectioning 
Frozen muscles were sectioned with a Microm HM 500 M at -23°C to 12 µm thickness 
and mounted on SuperFrost (Menzel GmbH & Co) microscope slides and air dried 
for 45 min at room temperature. To ensure that the outer most layer of cells remained 
intact, the muscle was not submerged in OCT (Tissue-Tek, Sakura Finetek, NL), but 
rather sectioned “free-standing” on a pre-holed cork plate where one end of the 
muscle was placed in the hole and surrounded with OCT. Microscope slides were 
stored at -20°C until analysis. 
 
3.5.2 Immunofluorescence 
Microscope slides were thawed for 15 min, after which all subsequent steps were 
performed at room temperature. The slides were rehydrated with phosphate buffer 
solution (PBS) containing 0.2% Triton X-100 (PBT) for 20 min, and blocked with PBT 
containing 1% BSA for 30 min. After this, incubation was performed using an antibody 
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solution in diluted PBT for 2 hours. Zenon Alexa Flour 555 rabbit IgG labelling reagent 
was used (Z-25305, Invitrogen, Sweden). Thereafter, the slides were washed 3 times 
for 15 min in PBT, and once in PBS for 5 min. The samples were fixated with 4% 
formaldehyde in PBS for 15 min and washed one more time in PBS for 5 min. 
Mounting was performed with ProLong Gold anti-fade reagent containing DAPI 
(P36931, Invitrogen, Sweden). The Zenon Alexa Flour 555 rabbit IgG labelling reagent 
(Fab-fragments) was used to fluorescently mark primary antibodies. The ratio between 
Fab-fragments and the antibody was 6:1 and the ratio of the dilution in the final 
working solution with PBT and the antibody solution was 6:1. Antibodies against 
phosphorylated insulin receptor (pIR-Tyr1146), phospho-Akt (pAkt-Ser473) and 
phoshpo-glycogen synthase kinase 3 (GSK3α/β-Ser21/Ser9) were used. Imaging was 
performed with a confocal microscope, inverted Zeiss LSM 510 META (Settings: 
Plane, multitrack, 12 bit, 1,024_1,024, 1,303.0 mm_1,303.0 mm, Plan-Neufluar 
100/0.3, and for the 630x magnifications, Plan-Apochromat 63x/1.4 Oil DIC). 
 
3.5.3 Quantification of immunofluorescence staining 
For all images taken, the setting of the microscope and camera were kept equal and 
background subtraction was not made. For each picture, three standardised regions of 
50 x 200 pixels were taken. This procedure was repeated for three muscle slices per 
specimen. Thus in total, nine regions from each muscle were analysed (Figure 6). 
 
Figure 6: Example of the three regions of 50 x 200 pixels that 
were used for the analysis. In this figure, an antibody against 
pIRTyr1146 was used to study insulin-stimulated EDL muscle. 
 
 
 
 
 
 
 
 
 
All nine regions were pooled together to obtain a robust estimate of the mean intensity. 
The standardized regions were extracted using MATLAB (MathWorks), and the 
pictures were rotated in Photoshop before excising the regions, so that an undamaged 
muscle region was facing the left side of the picture (Figure 7). 
 
 
Figure 7: Example of 
unsorted and sorted 
regions of 50x500 
pixels treated as a 
matrix of pixel values, 
divided into 9 groups of 
50 pixels each. 
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The standardised region was treated as a matrix and aligned so that the border of 
muscle section reflected the first pixel column. The matrix was then divided into 9 
groups of 50 pixels, and for each, the group mean was calculated to get a single set of 
data. Data were normalised against group 1 in the matrix, and against the control of 
each group to determine whether any difference occurred between the treatments 
(Figure 7). 
 
3.5.4 Capillary staining 
Capillary staining of skeletal muscle was performed with an indoxyl-tetrazolium 
method for alkaline phosphatase, which reveals the enzyme located in the capillary 
endothelium (Ziada et al., 1984). Tibialis anterior, Soleus and EDL were bundled 
together and sectioned simultaneously. Staining was performed as described earlier 
(Ziada et al., 1984). Muscle sections were incubated for 1 hour at 37°C, using an 
incubation medium composed of: nitroblue tetrazolium (Sigma), 30 mg; 5-bromo 4-
chloro 3-indolyl phosphate p-toluidine salt (Sigma), 6 mg in 30 ml of a buffer 
containing 6.9 mM MgS04 and 27.5 mM NaB02, pH adjusted to 9.2-9.4 with boric acid. 
A 5 min post-fixation in sucrose buffered formalin (4% formaldehyde, pH 7.3, 300 
mOsmol; 5 min) was performed after rinsing. Thereafter, muscle sections were alcohol 
dehydrated and mounted. The free-ware program Image-J (http://rsbweb.nih.gov/ij/) 
was used for analysis. With the Image-j program background was subtracted, threshold 
adjusted, and the image processed to binary and finally subjected to watershedding. 
Thereafter, the stained capillaries were counted with the “analyse particle” function. 
The number of fibres per section was counted manually from the unprocessed picture. 
 
 
3.6 LUMINEX SYSTEM 
The Luminex system used here is the Bio-Plex 200 system from Bio-Rad (Bio-Rad, 
Richmond, CA). The Bio-Plex 200 system works on the Luminex xMAP 96-well 
platform format. This technology (theoretically) permits simultaneous detection of up 
to 100 different analytes in one sample. The Luminex system uses an array of up to a 
100 sets of beads with a diameter of 5.6 µm. Each set of beads has an internal colour 
which gives the bead an identity number from 1-100. The core of the system is the bead 
with the internal colour which is coated with antibodies of a particular target. The Bio-
Plex 200 machine has two lasers, one that confirms the internal colour of the bead and 
thereby the particular target, and another laser by which the machine quantifies the 
actual amount of the target bound to the antibodies of the bead. The advantage of the 
Luminex xMAP technology is the possibility of multiplexing, meaning that the 
antibody coated beads can be mixed and up to (theoretically) 100 different targets 
which can be analysed for each and every well of the plate. Usually each kit also comes 
with a standard curve so that the outcome may be related back to an absolute 
concentration of the particular target (www.bio-rad.com). 
 
3.6.1 Luminex assay 
The Luminex kits used were obtained from Bio-Rad, special ordered in a 3-plex 
fashion, for pIR, pAkt, and pGSK3, (all these analytes are commercial available). The 
assay was performed according to the manual for the phosphoprotein kit (www.bio-
rad.com). 
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3.7 CELL CULTURE OF HUMAN SKELETAL MUSCLE 
Muscle biopsies were obtained from rectus abdominis during abdominal surgery, with 
approval from the donors and as per detailed in ethical permit 2005/1080-31/4 from 
Karolinska Institutet. Subjects were 61±5 years and had a BMI of 26 kg/ m2 and no 
known metabolic disorders. 
 
3.7.1 Cell culture 
From the muscle biopsies, the satellite cells were isolated with trypsin and 
collagenase digestion. Released satellite cells were cultured to myoblasts and 
differentiated into myotubes with Dulbecco’s modified Eagle’s serum (DMEM) as 
described (Al-Khalili et al., 2003; Al-Khalili et al., 2004). Ham’s F-10 medium, 
foetal bovine serum, penicillin, fungizone and streptomycin purchased from Gibco 
BRL (Invitrogen, Stockholm, Sweden), radioactive reagents were purchased from 
Amersham, all other reagents were purchased from Sigma. 
 
3.7.2 siRNA transfection 
Lipofectamine 2000 (Invitrogen) was used as transfection reagent when transfecting the 
cultured myotubes. Myotubes were grown on a 6-well plate and differentiation media 
was changed to antibiotic free media on day two of myotubes differentiation protocol. 
Transfections were performed on day zero and on day two with a pool of siRNAs 
(Dharmacon, Chicago, IL) against the human NT5C2 or scrambled sequence as a 
control. After transfection myotubes were washed with PBS, after which DMEM with 
2% foetal bovine serum was added to each well. On day six, since the start of the 
differentiation, the myotubes were serum starved overnight and incubated without 
(basal) or with 1 mM 5-aminoimidazole-4-carboxamide-1-b-4-ribofuranoside 
(AICAR, from Toronto Research Chemicals Inc, Ontario Canada) before each assay. 
 
3.7.3 mRNA expression analysis 
Before RNA extraction, the myotubes were washed three times with RNase free PBS. 
RNeasy minikit (Qiagen). Reverse transcription was performed with the super script 
First Strand Synthesis System from Invitrogen. Assays were performed in duplicates in 
the Prism 7000 Sequence Detector using TaqMan probes from Applied Biosystems. 
The relative quantities of the target transcripts were calculated after data normalisation 
with the standard curve method. RNA from skeletal muscle biopsies were isolated 
using TRIZOL reagent (Invitrogen). 
 
3.7.4 5’-nucleotide activity 
Nucleotidase activity was measured as release of [3H]-adenosine from 2-[3H]-AMP or 
[3H]-inosine from 8-[3H]-IMP. Homogenate (20 µl) was incubated at 30°C for 15 min 
in 50 µl buffer containing 100 mM-Tris-HCl, 2 mM Mg-Cl2 and 10 mM β-glycero P-
Na, with either 2-[3H]-AMP (200 mM, 5µCi) or 8-[3H]-IMP (200 mM, 1 µCi). The 
addition of 10 µl 150 mM ZnSO4 and 10 µl of saturated Ba(OH)2, to precipitate un-
hydrolyzed AMP, terminated the incubation. Samples were placed on ice for 10 min 
and subjected to centrifugation at 13000 rpm at 4°C for 15 min. The radioactivity from 
the supernatant was determined by β- scintillation counting (Belsham et al., 1980).  
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3.7.5 Palmitate oxidation 
Lipid oxidation in myotubes was determined using [3H]-palmitic acid and tritiated 
water was measured (Rune et al., 2009). Myotubes were washed once with PBS and 
then incubated for 4 hours without (basal) or with 1 mM AICAR in DMEM (1 g 
glucose/L) media supplemented with 0.2% fatty acid free BSA and 0.5 µCi palmitic 
acid [9-10(n)-3H]. The cell supernatant (0.2 ml) was mixed with 0.8 ml charcoal 
slurry (0.1 g charcoal powder in 1 ml 0.02 M tris-HCl buffer, pH 7.5) and shaken for 
30 min to absorb non-metabolized palmitate. Thereafter, the samples were subjected 
to centrifugation at 13,000 rpm for 15 min, and radioactivity was measured from the 
tritium bound water in 0.2 ml of the supernatant. Samples were processed by liquid β-
scintillation counting. 
 
3.7.6 Glucose uptake 
Glucose uptake was assessed in myotubes incubated for one hour without or with 
insulin (120 nM) or AICAR (1 mM). Myotubes were incubated in glucose-free and 
serum-free DMEM. Thereafter, [1,2-3H]-2-deoxy-D-glucose (0.33 µCi/ml) and 10 µM 
unlabelled 2-deoxy-D-glucose was added and myotubes were incubated for a 
subsequent hour in glucose-free DMEM (Al-Khalili et al., 2003; Al-Khalili et al., 
2004). Experiments were performed in triplicates and normalised against protein 
concentration (BCA Protein Assay Kit, Thermo Scientific, Rockford, IL). 
 
3.7.7 Glucose incorporation into glycogen 
The conversion of labelled glucose into glycogen was used as estimated of glycogen 
synthesis (Al-Khalili et al., 2003; Al-Khalili et al., 2004). Myotubes were incubated for 
90 min without or with insulin (120 nM), in DMEM containing 5 mM glucose and D-
[U-14C] glucose (1 μCi/ml; specific activity of 0.18 Ci/mol). Experiments were 
performed in triplicates.  
 
3.7.8 Glucose oxidation 
Glucose oxidation was measured in myotubes incubated for four hours without or with 
insulin (120 nM) or AICAR (1 mM). Myotubes were incubated in DMEM containing 
0.1 % fatty acid free BSA, D-[U-14C] glucose (1 μCi/ml; specific activity of 0.18 
Ci/mol (Amersham). 1 mM AICAR and 120 nM insulin in respective wells. 
Thereafter, protozol (150 µl, aqueous based tissue solubilizer, Perkin Elmer Life 
Science) was added to a centre-well hanging in the middle of each dish, and 
perchloric acid (150 µl, 35%) was added to the medium. After one hour of incubation, 
the centre-well was removed and subjected to scintillation counting. 
 
3.7.9 Media lactate measurement 
To measure lactate release into media from myotubes, 100 μl of media was collected in 
duplicates after an overnight incubation without or with AICAR (1 mM) in serum-free 
DMEM. The A-108 kit (Biochemical Research Service Centre, University of Buffalo, 
Buffalo, NY) was used to determine lactate concentrations (Bouzakri et al., 2008). 
 
3.7.10 Measurement of nucleotides 
Nucleotides were measured in differentiated human myotubes and mouse tibialis 
anterior muscle. Myotubes were grown on 10 cm dishes, washed three times with ice 
cold PBS and scraped into 300 μl of ice cold perchloric acid (5%). The tibialis 
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anterior muscle specimens were crushed to powder in liquid nitrogen and then 
homogenised in 0.2 ml perchloric acid (5 %). Thereafter, the samples were subjected 
to centrifugation at 14,000 rpm at 4ºC for 3 min, and 0.22 ml solution of equal parts 
of 1 tri-n-octylamine and 1,1,2,-trichlorotrifluoroethane was added to the supernatant. 
The samples were vigorously mixed using a vortex. Thereafter, samples were 
subjected to a second round of centrifugation at the same settings as described earlier, 
and the upper aqueous layer was removed. To each sample, 0.22 ml of the same 
solution was added. Finally, 20 μl of the last aqueous phase was analysed with 
capillary electrophoresis and on-column isotachophoretic preconcentration, with a 
leading buffer (50 mM sodium phosphate, 50 mM NaCl, pH 5.2) and a tailing buffer 
(100 mM MES/Tris pH 5.2), hydroxyethyl-cellulose (0.2 %) added to each buffer to 
decrease the electro-osmotic flow. UV spectrophotometry (260 nM) was used to 
detect nucleotide peaks with the System Gold Software (Beckman). The peak areas 
were used to calculate nucleotide ratios after correction for retention time (Sakamoto 
et al., 2005).  
   19 
4 RESULTS AND DISCUSSION 
To understand human diseases, and in particular T2DM, animal models are often used 
for studying the particular mechanism involved in the disease. Clearly animal models 
do not fully recapitulate the human condition and care must be taken when interpreting 
results from animal models (Neubauer & Kulkarni, 2006; Tkacs & Thompson, 2006). 
As a complementary experimental model, cell cultures may also be used. These are 
either commercially available cell lines or cell material from individual animals or 
humans. One approach is the culture of myotubes from human biopsy material, and 
subsequent use of these cultured myotubes for metabolic measurements. The caveat 
with myotubes from skeletal muscle is that they do not fully differentiate into 
contractile muscle when cultured and grown in vitro. For example, they express 
relatively low levels of the GLUT4 protein, and high levels of the GLUT1 protein, as 
compared to adult muscle. This is reflected by the different metabolic assays of 
cultured myotubes. 
 
 
4.1 METABOLIC MEASUREMENTS ON SKELETAL MUSCLE IN VITRO 
The experimental setup with muscles that are dissected and incubated in vials 
containing oxygenated solution is a common way to study metabolic pathways and 
drug targets (Garber et al., 1976). There are, however, several important factors with 
this experimental setup that differ from the in vivo situation. Maybe the most crucial 
difference in vitro is that the muscle becomes dependent on diffusion rather than on 
blood flow to transfer nutrients across the cell membrane (Van Breda et al., 1990). 
 
4.1.1 Skeletal muscle properties 
In a muscle the most oxidative fibres are gathered around the largest blood vessels, 
which are located in the centre of the muscle. This means that the oxygen has a 
relatively shorter distance to cross into the oxidative fibres. This situation is reversed 
during in vitro incubation, since oxygen now has to diffuse from the outside of the 
muscle and hence is the most oxidative fibres are furthest away from the oxygen source 
(Lexell et al., 1994; Wang & Kernell, 2001; Widmer et al., 2002; Holtermann et al., 
2008). In paper I, the spatial insulin signalling was investigated during in vitro 
incubation of skeletal muscle. In this analysis of the muscle it was possible to determine 
if insulin was able to diffuse through muscle and activate the insulin signalling cascade 
evenly all the way through the muscle specimen. 
 
 
4.2 INSULIN SIGNALLING IN VITRO 
The aim of paper I was to investigate whether insulin diffused throughout the whole 
muscle specimen during in vitro incubation in sufficient amounts to activate the insulin 
signalling cascade. The rationale behind this is a former study performed using the 
same in vitro experimental methodology (Sogaard et al., 2009). The main result in the 
previous study was that the incubated muscles had increased protein abundance of 
markers for hypoxia and apoptosis (Sogaard et al., 2009), together with an area of 
glycogen depletion in the core of the muscle (Maltin & Harris, 1985; Sogaard et al., 
2009). However it could not be ruled out that the lack of glycogen in the core of the 
incubated muscle specimens was not due to insufficient activation of the insulin 
signalling cascade. As increased glucose uptake is dependent on insulin stimulation 
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(James et al., 1988), a reduced activation of the insulin signalling pathway due to 
limitation in insulin diffusion could also result in a depleted area of glycogen. 
 
As outlined in section 1.6.2, the first phosphorylated protein due to insulin stimulation 
is the receptor for insulin which is located in the cell membrane and is the molecule 
through which insulin mediates it action (De Meyts et al., 1973). The binding of insulin 
results in a conformational change of the IR which lowers the distance between the 
tyrosine kinase domains which in turn gets activated (Lee et al., 1997). Each of the 
activated tyrosine kinase domains catalyses the phosphorylation of the other kinase 
domain, a process named auto-phosphorylation (Van Obberghen et al., 1983). In 
T2DM patients, binding of insulin to IR is normal (Ciaraldi et al., 2002) or impaired 
(Caro et al., 1987). Furthermore, phosphorylation of IR have been showed to be normal 
(Caro et al., 1987; Krook et al., 2000) or impaired (Arner et al., 1987; Maegawa et al., 
1991). The insulin signalling cascade is then perpetuated from the activated IR through 
PI3-K and the generation of phosphatidylinositol (3,4,5)-triphosphate to activate Akt, 
which is a central node in the insulin signalling cascade. Akt is also known as Protein 
Kinase B which is required for induction of glucose transport. Impairments in insulin 
signalling at the level of Akt in insulin-resistant T2DM patients have been 
demonstrated (Krook et al., 1998). Akt works as an inhibitor of GSK3 which it 
phosphorylates to its inactive form, GSK3 can in its active form phosphorylate GS 
thereby make GS less effective. Elevated levels of GSK3α can induce insulin resistance 
in human skeletal muscle cells (Cross et al., 1995; Ciaraldi et al., 2007). 
 
4.2.1 Homogenised muscle 
The first measurements in paper I were performed on homogenised whole muscle 
samples with the multiplex detection technique Bio-Plex 200, which quantifies relative 
concentrations of the analytes (Jones et al., 2009). The chosen analytes were pIR, pAkt 
and pGSK3α/β which are measures of the function of the canonical insulin signalling 
pathway. We provide evidence that insulin-stimulated muscle had a higher level of the 
phosphorylated proteins as compared to basal samples. Thus, we can conclude that 
insulin signalling works appropriately in the muscle specimen. However, it has to be 
pointed out, that by homogenising the muscle specimens, it is only the average value 
for the whole muscle that is measured and therefore spatial differences can be masked, 
as has been noted for spatial glycogen distribution (Sogaard et al., 2009). 
 
4.2.2 Sectioned muscle  
From the results discussed in 4.2.1; the natural next step would be to go into the spatial 
resolution of the muscle specimen and assess different points in the insulin signalling 
cascade. We next determined whether there is a spatial heterogeneity in the canonical 
insulin signalling cascade following insulin-stimulation in in vitro incubated muscle. 
To assess this, we utilised immunofluorescence techniques to study transversal sections 
of the muscle, and measured pIR, pAkt and pGSK3α/β. We demonstrated an activation 
of the insulin signalling cascade throughout the muscle specimen in response to insulin 
stimulation. The results also indicated insulin signalling was enhanced in the centre of 
the muscle, specimens at the time point studied. We found this particularly interesting, 
since if insulin diffusion was limiting the signalling cascade, we would have expected 
decreases in signalling intensity towards the core of the muscle specimens. However, 
insulin signalling was enhanced in the centre of the muscle and we speculate that this 
may be due to the fact that the oxidative fibres are located more centrally in muscle 
specimens (Wang & Kernell, 2001) and that the oxidative fibres are more insulin 
sensitive (Song et al., 1999). Taken together, we conclude that insulin diffusion is 
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sufficient to activate insulin signalling throughout the muscle specimen during in vitro 
incubation. However, as the concentration of insulin was not measured within the 
muscle specimens, it is not possible to conclude whether the insulin cascade was fully 
activated. Another possibility is to perform a time course and measure the activation of 
insulin signalling, however this was not performed. 
 
 
4.3 KNOCK DOWN OF NT5C1A IN SKELETAL MUSCLE 
In paper II was electroporation utilised to reduce protein expression of NT5C1A 
enzyme in tibialis anterior muscle of mice. In parallel, protein expression of NT5C2 
enzyme was reduced in cultured human using siRNA. There are two major benefits 
with the electroporation system, compared with cultured myotubes. Firstly; both control 
and knock down conditions are studied within the same animal using contralateral 
muscles. In cultured myotubes, the controls come from the same origin but are grown 
on different plates. Secondly; the silencing is performed in an in vivo system such that 
the overall effect on metabolism may be more physiologically relevant i.e. the in vivo 
system acclimatises to the changes that the silenced protein confers, during the week 
until experiment is finalised. 
 
4.3.1 Electroporation method development 
Initially, the electroporation assay was conducted as described earlier (Mir et al., 1999). 
Muscles were exposed through an incision in the skin and injected with a syringe 
containing the specific DNA to be electroporated. The skin was then sutured and the 
muscles were electroporated as described (Mir et al., 1999). This method resulted in 
transfection efficiency of approximately 30-60% of muscle fibres when assessing the 
cross sectional area of the muscles 7 days after transfection (Figure 8). 
 
 
Figure 8: Transfection efficiency without the hyaluronidase 
pre-treatment. Electroporation performed with the 
pDsRed2-C1 plasmid from CLONETECH. 
 
 
 
 
 
 
 
The second assay also followed established protocols (McMahon et al., 2001). For this, 
the tibialis anterior was targeted through the skin, and because of this, an incision was 
unnecessary. The first step was a pre-treatment of the muscle with hyaluronidase (30 µl 
with 1 U/µl) for two hours before the actual injection of DNA. This step increases the 
transfection efficiency dramatically (McMahon et al., 2001). The pre-treated animals 
were put back into a cage until the DNA was injected (30 µl of plasmids, 1 µg/µl), and 
the electrical stimulation with 220 V/cm (Figure 9). A contact gel (Ultra/Phonic 
Conductivity Gel by Pharmaceutical Innovations, Inc., Newark, NJ, USA), was 
applied to whole leg to ensure good conductivity with the calliper electrodes, square 
wave electrical stimulation was performed with the ECM 830 system (BTX, Harvard 
apparatus, Holliston, MA). There was a difference in conductivity among different 
brands of contact gel. The best gel for electroporation should have a conductivity of 5 
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mS/cm. However, since there are differences in tissue conductivity vary not only 
between animal strains and age, but also with the preparation of the leg before 
electroporation (i.e. shaving and cleaning). The gel used here (Ultra/ Phonic 
Conductivity Gel) had a conductivity of ~1 mS/cm as described earlier (Ivorra & 
Rubinsky, 2008). Thus, this gel could be regarded as in the lower range of 
conductivity for suitable gels. 
 
 
Figure 9: 
Injection of 
tibialis anterior 
through the skin 
of the leg and 
the electrical 
stimulation. 
 
Figure 10 shows the muscle pre-treated with hyaluronidase in order to get a higher 
transfection rate (Images are taken 7 days after electroporation). The achieved 
transfection rate with control plasmid (CLONTECH, pZsGreen1-C1) covered 
approximately 80-90% of the cross sectional area of the muscle. 
 
Figure 10: Transfection 
efficiency with hyaluronidase 
pre-treatment of tibialis 
anterior. Leg without skin in 
ordinary “room light” and 
cross section of the same 
muscle viewed in 
microscope. Note the fascia 
that divides the inner part 
(red/oxidative) from the other 
(white/glycolytic) part of 
tibialis anterior. 
Electroporation performed 
with the pZsGreen1-C1 
plasmid from CLONETECH. 
 
 
One caveat with this method is that the fascia in the tibialis anterior can work as a 
barrier against the injected DNA. In this case, not all of the fibres will be surrounded or 
bathed in DNA before the electrical stimulation. This may account for a lower 
expression in the inner part of the muscle (Figure 10, left part of muscle in the cross 
sectional picture). 
 
4.3.2 Expression confirmation in vivo 
The next issue was to confirm that the electroporation efficiency before sacrificing the 
animal, or performing an in vivo experiment. This expression confirmation issue was 
solved by using a laser pointer that concentrated all light at and into the muscle. This 
meant that the emission light could be observed outside the muscle (and animal) and 
not be disturbed by excitation light (Figure 11). 
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Figure 11: In vivo 
excitation of Tibialis 
Anterior transfected 
with the pDsRed2-C1 
plasmid from 
CLONTECH, laser 
source is of 532 nm 
wavelength and 5 
mW. 
 
 
 
The laser source used for this purpose was of approximately the same effect as the laser 
in a conventional confocal microscope (5 mW and wavelength of 532 nm). The 
excitation light of 532 nm (green laser light) can excite a red fluorescent protein to emit 
red light. The pDsRed2-C1 a red fluorescent plasmid from CLONTECH was used 
(Figure 11). The main drawback of this expression confirmation study was that high 
expression of the target DNA was required to see emitted light without any extra 
equipment such as a whole body scan for fluorescence light. The method worked well 
when a transfection efficiency of approximately 50% was achieved. If the transfection 
efficiency was below 50%, it was challenging to see emitted light in ordinary day light. 
 
4.3.3 Phosphorylation of AMPK and ACC 
AMPK has long been regarded as a promising pharmacological target for the treatment 
of metabolic disease. Overexpression of an activated form of the AMPKγ3 subunit in 
mouse skeletal muscle has been shown to increase lipid oxidation and protect from 
diet-induced insulin resistance (Barnes et al., 2004). AICAR is a pharmacological 
activator of AMPK, which has been shown to improve insulin sensitivity and glucose 
tolerance in diabetic animal models (Bergeron et al., 2001; Fiedler et al., 2001; Halseth 
et al., 2002; Song et al., 2002). AICAR is transported into the cell via the adenosine 
transporter. Once inside the cell, the enzyme AK transforms AICAR to 5-
aminoimidazole-4-carboxamide ribonucleotide (ZMP) (Figure 2). ZMP is an analogue 
of AMP and the increased ratio of ZMP/ATP activates AMPK (Corton et al., 1995; 
Holmes et al., 1999). The disadvantage of AICAR for the treatment of metabolic 
disease is that it has other effects which not are linked to AMPK activation (Young et 
al., 1996), and ZMP also activates all enzymes that are activated by AMP (Fujii et al., 
2006). The half-life of ZMP is also longer than the half-life of AMP since ZMP gets 
accumulated within the cell (Dixon et al., 1991). After reducing expression of the 
NT5C1A enzyme by electroporation of tibialis anterior muscle of mice, we observed 
an increased phosphorylation of both AMPK and ACC by 60% and 50% respectively. 
Furthermore, the AMP to ATP ratio was increased 17% in NT5C1A depleted muscle 
(Figure 12).  
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4.6.1 TBC1D1 in humans 
A R125W mutation in TBC1D1 has been linked to a predisposition for severe obesity 
in humans (Stone et al., 2006). Increased risk of T2DM has also been linked to 
TBC1D1 via single-nucleotide polymorphism (SNP) hits in the TBC1D1 domain 
(Zeggini et al., 2007). The R125W mutation is located in the phosphotyrosine-binding 
site, which is involved in protein-protein interaction (Stone et al., 2006). 
Overexpression of the R125W mutant by electroporation in mice decreased insulin-
stimulated glucose uptake (An et al., 2010). Since TBC1D1 is an Akt substrate, and is 
inactivated in its phosphorylated state, the R125W mutation might prevent Akt from 
phosphorylating TBC1D1, and prevent inactivation. This would result in a 
constitutively active GAP domain, which in turn would act as a brake on GLUT4 
translocation via the inactivation of Rab-GTP to Rab-GDP. 
 
4.6.2 TBC1D1 insulin-stimulated glucose uptake 
The TBC1D1-deficient mouse strain studied here would hypothetically not have a 
brake on GLUT4 translocation because the TBC1D1 protein with the GAP-domain 
which makes the inactive form of Rab (Rab-GDP) is not produced. The expected 
phenotype of the TBC1D1-deficient mouse would be an increased rate of glucose 
uptake and fatty acid oxidation in the muscles in which TBC1D1 is endogenously 
expressed. 
 
4.6.3 Clamp method development 
In the original clamp surgery, the visible end of the catheter was placed through a 
plastic stopper that was in turn placed in an incision made on the neck of the mouse. 
The extra length of the catheter was placed under the skin towards the tail, and on the 
day of experiment the catheter was pulled out through the plastic stopper 
(approximately 10 cm) and connected to the infusion pump. This sometimes resulted in 
attachment of the catheter as the incision healed and inflammation at the protruding end 
of the catheter. In some cases when inflammation was noted, the animal failed to gain 
weight during the recovery week. To avoid this, the surgery was modified as follows: 
the skin itself was used as a stopper, instead of the plastic stopper. This was possible 
because the catheter already had a small stopper attached. Hence the incision for 
handling the catheter was made on the side of the neck, and on top of the neck (where 
the previous incision would have been) a small skin puncture was made so that the 
catheter could fit through (Figure 15). 
 
 
Figure 15: Clamp surgery 
with incision on the side of the 
neck, and the skin used as 
stopper for catheter. 
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¾ In paper III, we investigated the metabolic role of TBC1D1 in skeletal muscle 
metabolism. We provide evidence that the Rab-GTPase activating protein 
TBC1D1 is involved in metabolic regulation and that functional TBC1D1 is 
required for AICAR- and contraction-induced in vitro metabolic responses, 
implicating a role in energy-sensing signals. We show that TBC1D1-deficiency 
increases insulin-stimulated glucose uptake in tibialis anterior and EDL muscle 
during 2-DOG clamp. TBC1D1-deficiency also gives increased hepatic insulin 
sensitivity during the GTR clamp. 
 
 
Figure 19: The main pathways studied in this thesis. The NT5C1A protein was found to be a negative 
regulator of insulin-stimulated glucose uptake and fatty acid oxidation. TBC1D1 has a negative effect on 
glucose uptake and on fatty acid oxidation. 
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5 CONCLUSIONS AND FURTHER PERSPECTIVES 
In this thesis work, new data regarding insulin signalling and molecular targets 
controlling metabolism have been revealed. Specific conclusions of each study include 
the following:  
 
Paper I: Insulin action is not restricted in isolated skeletal muscle preparations due to 
insufficient diffusion of the hormone during in vitro incubation. Thus, isolated skeletal 
muscle preparations are a viable technique to study the acute effects of insulin on signal 
transduction. 
 
Paper II: Endogenous expression of NT5C enzymes is likely to inhibit basal lipid 
oxidation and glucose transport in skeletal muscle. Thus, pharmacological approaches 
to reduce 5'-nucleotidase expression or activity may promote metabolic flexibility in 
type 2 diabetes mellitus. 
 
Paper III: TBC1D1 protein is linked to the regulation of GLUT4 protein and glucose 
uptake in skeletal muscle. Enhanced hepatic insulin sensitivity and enhanced glucose 
homeostasis in glycolytic muscle from TBC1D1-deficient mice supports the role of 
TBC1D1 as a Rab-GTPase activating protein. Thus, functional TBC1D1 is required for 
contraction and AICAR responses in vitro, which suggests that TBC1D1 is involved in 
sensing or regulation of oxidative pathways. 
 
The overarching conclusion of this thesis is that molecular pathways controlling 
glucose uptake in skeletal muscle are important to understand to eventually prevent and 
treat T2DM. We conclude that insulin signalling is functional in the in vitro incubated 
skeletal muscle specimens. Moreover, the molecular switches TBC1D1 and NT5C1A 
have high impact on glucose uptake in skeletal muscle. The results presented in this 
thesis may impact the understanding of metabolic pathways contributing to the 
development of insulin resistance in T2DM 
 
Future studies to investigate whether there is a connection between NT5C1A and 
exercise training and whether NT5C1A enzymes impact mitochondria function may be 
warranted. In addition, future studies to determine the whether TBC1D1 is altered in 
skeletal muscle from people with T2DM or after exercise training are of interest. Other 
work may be directed towards understanding whether there is an internal relationship 
between NT5C1A and TBC1D1. Another perspective is pursuing the possibility to use 
the NT5C1A enzyme and the nucleosides as molecular marker for metabolic status in 
T2DM patients. The concept of using nucleosides as molecular marker is already being 
used in case of cancer and liver diseases. 
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